Fiscal Note

State of Alaska 2018 Legislative Session

Bill Version: SB 198

Fiscal Note Number:

(S) Publish Date: 4/4/2018

Identifier: SB198-UA-AC-3-27-18 Title: **UAA LONG-ACTING CONTRACEPTION STUDY** Department: University of Alaska Appropriation: University of Alaska

Sponsor: **KELLY** Allocation: **Anchorage Campus**

OMB Component Number: 753

Expenditures/Revenues

Requester: Senate Finance

(Thousands of Dollars) Note: Amounts do not include inflation unless otherwise noted below.

		Included in				·	
	FY2019	Governor's					
	Appropriation	FY2019	Out-Year Cost Estimates				
	Requested	Request					
OPERATING EXPENDITURES	FY 2019	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Personal Services	93.1		103.9	98.1			
Travel							
Services	30.0		60.0	60.0			
Commodities	25.0		25.0	5.0			
Capital Outlay							
Grants & Benefits							
Miscellaneous							
Total Operating	148.1	0.0	188.9	163.1	0.0	0.0	0.0

Fund Source (Operating Only)

1004 Gen Fund (UGF)	148.1		188.9	163.1			
Total	148.1	0.0	188.9	163.1	0.0	0.0	0.0

Positions

Full-time				
Part-time				
Temporary				

Change in Revenues

onango m novonaoo							
None							
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Estimated SUPPLEMENTAL (FY2018) cost: 0.0

(separate supplemental appropriation required)

(discuss reasons and fund source(s) in analysis section)

Estimated CAPITAL (FY2019) cost: (discuss reasons and fund source(s) in analysis section)

(separate capital appropriation required)

ASSOCIATED REGULATIONS

Does the bill direct, or will the bill result in, regulation changes adopted by your agency?

If yes, by what date are the regulations to be adopted, amended or repealed?

Why this fiscal note differs from previous version/comments:

This new version of the Fiscal Note makes two changes: 1) it removes revenues, which were incorrectly included in the original version. The bill itself will not result in a change of revenues to UA and 2) changes the fund source to 1004 General Funds. The original version incorrectly listed the fund source as 1037 GF/Mental Health.

Prepared By: Michelle Rizk Phone: (907)322-9625 Date: Division: University of Alaska 03/26/2018 02:30 PM Michelle Rizk Date: Approved By: 03/26/18 Agency: University of Alaska

FISCAL NOTE ANALYSIS

STATE OF ALASKA 2018 LEGISLATIVE SESSION

Analysis

Through SB 198, the University of Alaska Anchorage Center for Alcohol and Addiction Studies will conduct a study to evaluate the feasibility and effectiveness of providing Long Acting Reversible Contraception (LARC) to women with substance abuse disorders who are at high risk for unintended pregnancies that may result in prenatal drug or alcohol exposure. The study will be done in collaboration with hospitals and health care providers in Alaska who treat women with substance abuse disorders.

Project Outcomes:

- Establish a collaborative network of service providers treating women at high risk of Neonatal Abstinence Syndrome (NAS) and/or Fetal Alcohol Spectrum Disorders (FASD)
- Assess the feasibility and utility of providing LARCs to the Neonatal Abstinence Evaluation Support Treatment (NEST)
 program
- Develop a cohort of women and children receiving NEST services for long term follow-up
- Provide a data-driven framework and foundation for a comprehensive LARC strategy in Alaska
- Provide a full report to the Alaska State Legislature and Key Stakeholders

The study will begin in July 2018 and be conducted in three phases:

Phase 1: Development (July 2018 - March 2019)

Establish and convene advisory panels, develop clinical protocols, research procedures

Phase 2: Implementation and Evaluation (March 2019 - May 2020)

Implement referral protocols, assemble cohort, data collection, network collaboration

Phase 3: Data Analysis and Reporting (April 2019 - June 2021)

Data analysis, strategy development, outcomes, reporting, strategy recommendations

Funding covers personnel costs for time contributed by principal investigator and co-investigators; contracted case management, and medical commodities necessary for the study to include the cost of providing contraception to project participants without health insurance.

Two interim reports will be provided: June 30, 2019 and June 30, 2020, and a final report will be due by June 30, 2021.

(Revised 9/26/17 OMB/LFD) Page 2 of 2